<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Lancet Reg Health Am</journal-id><journal-id journal-id-type="iso-abbrev">Lancet Reg Health Am</journal-id><journal-id journal-id-type="pmc-domain-id">4381</journal-id><journal-id journal-id-type="pmc-domain">lrhamers</journal-id><journal-title-group><journal-title>Lancet Regional Health - Americas</journal-title></journal-title-group><issn pub-type="epub">2667-193X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11876894</article-id><article-id pub-id-type="pmcid-ver">PMC11876894.1</article-id><article-id pub-id-type="pmcaid">11876894</article-id><article-id pub-id-type="pmcaiid">11876894</article-id><article-id pub-id-type="pmid">40040818</article-id><article-id pub-id-type="doi">10.1016/j.lana.2025.101030</article-id><article-id pub-id-type="pii">S2667-193X(25)00040-7</article-id><article-id pub-id-type="publisher-id">101030</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>The recent trend of twin epidemic in the United States: a 10-year longitudinal cohort study of co-prescriptions of opioids and stimulants</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Lee</surname><given-names initials="S">Seungyeon</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">e</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Song</surname><given-names initials="W">Wenyu</given-names></name><email>wsong@bwh.harvard.edu</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">e</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Bates</surname><given-names initials="DW">David W.</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Urman</surname><given-names initials="RD">Richard D.</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Zhang</surname><given-names initials="P">Ping</given-names></name><email>zhang.10631@osu.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp">&#8727;&#8727;</xref></contrib><aff id="aff1"><label>a</label>Department of Computer Science and Engineering, The Ohio State University, Columbus, OH, USA</aff><aff id="aff2"><label>b</label>Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA</aff><aff id="aff3"><label>c</label>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA</aff><aff id="aff4"><label>d</label>Department of Anesthesiology, College of Medicine, The Ohio State University, Columbus, OH, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA. <email>wsong@bwh.harvard.edu</email></corresp><corresp id="cor2"><label>&#8727;&#8727;</label>Corresponding author. Department of Biomedical Informatics, Department of Computer Science and Engineering, The Ohio State University, USA. <email>zhang.10631@osu.edu</email></corresp><fn id="fn1"><label>e</label><p id="ntpara0010">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2025</year></pub-date><volume>44</volume><issue-id pub-id-type="pmc-issue-id">483312</issue-id><elocation-id>101030</elocation-id><history><date date-type="received"><day>24</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>24</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-06 13:25:48.297"><day>06</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><title>Summary</title><sec><title>Background</title><p>In recent years, the use of central nervous system stimulant medications has increased among the population already using opioids, referred to as a &#8220;twin epidemic.&#8221; There is an increasing concern about its harmful outcomes in large populations. However, very few studies examined the co-prescription pattern of these two drug categories over a long period, and there is currently no clear restriction on stimulant prescriptions among patients under opioid treatment in the United States. The objectives of our study were to identify opioid prescription dosage time-dependent patterns and patient subgroups representing distinct trajectories on a national level in the recent 10 years, and to further investigate longitudinal associations between stimulant and opioid prescriptions and the impact of stimulant prescriptions on opioid dosage patterns.</p></sec><sec><title>Methods</title><p>We obtained patient records from MarketScan, one of the largest clinical databases of health insurance in the United States. 10 years (2012&#8211;2021) of prescription records and related patient profiles, who received at least two independent opioid prescriptions, were utilized for developing a group-based opioid dose trajectory model.</p></sec><sec><title>Findings</title><p>From an initial cohort including 22 million patients with 96 million opioid prescriptions, we developed a study cohort of 2,895,960 patients with a mean age of 43.9 years (standard deviation [SD] 13.0), of whom 1,244,077 (43%) were male. Significant geographical variations in opioid prescription frequency and dosage among four U.S. regions were observed. The trajectory model identified five distinct opioid dose groups. Stimulant prescription before the initial opioid prescription was positively associated with escalating opioid doses (odds ratio [OR]: 7.58; 95% confidence intervals [CI] 6.14&#8211;9.35, opioid dose increasing group compared to the decreasing group). Stimulant co-prescriptions were also associated with increasing opioid doses (OR: 1.73; 95% CI 1.40&#8211;2.14) and were identified in patients with a higher prevalence of opioid use disorder.</p></sec><sec><title>Interpretation</title><p>During the recent 10 years, stimulant prescription is positively associated with escalating opioid prescription activities in U.S. healthcare systems, suggesting co-prescriptions of these two types of drugs are an important contributing factor for a national-level twin epidemic. Healthcare leaders and policymakers should pay more attention to this issue and its potential harms.</p></sec><sec><title>Funding</title><p><funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source>, <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source>, and <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source>.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Twin epidemic</kwd><kwd>Opioid crisis</kwd><kwd>Trajectory analysis</kwd><kwd>Co-prescription pattern</kwd><kwd>Drug overdose</kwd><kwd>Patient safety</kwd><kwd>Stimulant prescription</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Research in context</title></caption><sec id="dtbox1sec1"><title>Evidence before this study</title><p id="p0015">In recent years, the use of central nervous system stimulant medications has increased among the population with opioid exposure, leading to what is referred to as a &#8220;twin epidemic.&#8221; The co-use of opioids and stimulants can potentially increase the risk of overdose and other adverse health outcomes, such as cardiovascular events, mental health problems, and even death. We searched PubMed on February 2024 using the terms (&#8220;opioid&#8221;) and (&#8220;dose&#8221; or &#8220;dosage&#8221;) and (&#8220;trajectory&#8221;) within the past 10 years. The search retrieved 110 studies, but only 15 were relevant to our research. These studies investigated opioid dosage patterns and examined the association between these patterns and the risk of overdose, death, opioid use disorders, and other comorbidities. With the additional term (&#8220;stimulant&#8221;), only two studies were found, neither of which was pertinent to associations between stimulants and opioids. Furthermore, we found no national-level evidence examining longitudinal associations between opioid and stimulant prescriptions, nor the impact of stimulant prescribing on opioid dosage trajectories. The relevant literature has typically focused solely on opioid doses and is often constrained to short-term studies, single sites, or small populations.</p></sec><sec id="dtbox1sec2"><title>Added value of this study</title><p id="p0020">Previous studies have suggested an increasing trend of co-use of these two types of drugs in patient populations, while no large-scale studies have confirmed this pattern on a national level. In this study, we examined longitudinal co-prescription patterns of opioid and stimulant drugs across U.S. healthcare systems and identified a significant positive correlation. Our results, for the first time, provided strong evidence of the emerging twin epidemic in the United States. Healthcare leaders and policymakers should pay more attention to this issue and its potential harms.</p></sec><sec id="dtbox1sec3"><title>Implications of all the available evidence</title><p id="p0025">Previous evidence has shown that the co-use of opioids and stimulants could synergistically reinforce dopamine signals and prolong the action of dopamine neuronal activities, leading to euphoric effects. Despite the potential enhanced abuse risk, there is no systematic regulation to guide or restrict co-prescription activities. Our results highlight the severity and prevalence of this issue in healthcare systems and the urgent need for developing corresponding prescription regulations. Our future research will further reveal potential causality mechanisms between co-prescription patterns and patient adverse outcomes.</p></sec></boxed-text>
</p><sec id="sec1"><title>Introduction</title><p id="p0030">The opioid epidemic refers to the widespread misuse and abuse of prescription opioids, such as oxycodone, hydrocodone, and fentanyl, as well as illicit opioids, such as heroin.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> This epidemic began in the late 1990s and has since resulted in a dramatic increase in opioid-related overdose deaths. In 2023, there were 81,083 opioid overdose deaths in the United States.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></p><p id="p0035">In recent years, there has been a significant increase in both opioid- and central nervous system stimulant medication-related overdose deaths.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> The opioid and stimulant epidemics are two intertwined public health crises that have been described as the &#8220;twin epidemic.&#8221;<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> Both epidemics involve the misuse and abuse of prescription and illicit drugs, and both have led to a significant increase in overdose deaths and other adverse health outcomes.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The twin epidemic has emerged due to the overlap between the two epidemics. Many individuals who misuse opioids also use stimulants, and vice versa.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> The co-use of opioids and stimulants can increase the risk of overdose and other adverse health outcomes, such as cardiovascular events, mental health problems, and even death.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref> The twin epidemic of opioid and stimulant abuse is particularly concerning because these drugs exert different effects on the body and can interact in unpredictable ways.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Addressing the twin epidemic requires a comprehensive approach that includes prevention, treatment, and harm reduction strategies.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> These strategies should be tailored to the specific needs of each individual who is affected by the twin epidemic.</p><p id="p0040">Despite the wealth of evidence supporting the potential enhanced abuse risk of co-prescription of stimulant and opioid drugs and the need for tailored strategies for individuals who might experience the twin epidemic, there have been no large-scale studies to evaluate longitudinal associations between stimulant prescription and opioid prescription trajectories, across U.S. healthcare systems. One study reported increased risk of overdose with co-use of opioids and stimulants<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> was solely based on provincial health records from Canada. The lack of evidence creates challenges for policymakers to initiate corresponding regulations to address potential harms with a systematic manner. Previous work has mainly focused on investigating opioid dosage trajectories only,<xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> and was often limited to short-term, single site or small populations.</p><p id="p0045">The objectives of our study were to identify opioid prescription dosage time-dependent patterns and patient subgroups representing distinct trajectories on a national level in the recent 10 years, and to further investigate longitudinal associations between stimulant and opioid prescriptions and the impact of stimulant prescriptions on opioid dosage patterns. Additionally, we investigated regional differences in opioid and stimulant prescribing patterns among four major regions of the U.S. to provide insights essential for developing targeted, region-specific policies to more effectively address the opioid and twin epidemics.</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Study design</title><p id="p0050">In this retrospective cohort study, we used large-scale longitudinal patient-level healthcare data from the MarketScan Commercial Claims and Encounters (CCAE), which provides some of the largest convenience samples available in proprietary U.S. databases&#8212;with over 293 million unique patients since 1995. The database contains de-identified, individual-level healthcare claims on a national scale and is primarily used to evaluate health utilization and services.</p><p id="p0055">We identified approximately 20 million patients with around 96 million opioid prescription records in the MarketScan database from Jan 1, 2012, to Dec 31, 2021. Of these, about 2.8 million patients met our study cohort selection criteria. Each patient had a comprehensive set of medical records, encompassing demographic characteristics, drug prescriptions, diagnoses, procedures, and other clinically relevant indicators with time information. The data utilized for this study included patient demographics, diagnosis, and drug prescription claims. Diagnoses and drug codes are defined according to the International Classification of Diseases (ICD-9/10) and National Drug Codes (NDC), respectively. Drug records include the number and type of drugs dispensed, the route of administration, days' supply, and the strength per unit. We included only non-missing records in these fields. No substantial missingness was observed across all regions and age groups (126,099/97,049,173 [0.1%]), suggesting completeness of the dataset and a very small amount of missing at random.</p></sec><sec id="sec2.2"><title>Participants</title><p id="p0060">The study cohort included all individuals who received at least two independent opioid prescriptions at different times. Patient eligibility required at least 12&#160;months of continuous enrollment before the index date&#8212;the date of the first opioid prescription&#8212;to establish the baseline period, and at least two months of continuous enrollment after the index date to define the follow-up period. Individuals were excluded if they were younger than 18 years on the index date or had been diagnosed with any cancer. Additionally, those who had been prescribed buprenorphine before the eligible opioid prescriptions were excluded, as buprenorphine is primarily used to treat opioid use disorder.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> The study period begins at the index date and follow-ups for each individual ended after 9 years or upon loss to follow-up (the end of the continuous enrollment), whichever occurred first. The number of included and excluded patients is detailed in <xref rid="appsec1" ref-type="sec">Supplementary Figure&#160;S1</xref>.</p><p id="p0065">Opioids included in the study were codeine, dihydrocodeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, opium, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, and sufentanil (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S1</xref>). We included only oral prescriptions, and excluded patches, injections, and other routes. Opioid and stimulant drugs were identified using the National Drug Codes, including their combination with other drug classes. The list of stimulants included in the study is provided in <xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S1</xref>.</p></sec><sec id="sec2.3"><title>Study variables</title><p id="p0070">All opioid prescriptions were converted to oral morphine milligram equivalents (MMEs). We determined the patient's daily dose of opioids in MME (mg/day) by multiplying the strength and quantity of opioids dispensed on the day by published conversion factors, expressed as: strength per unit&#160;&#215;&#160;(number of units/days supplied)&#160;&#215;&#160;MME conversion factor. We calculated the monthly MME of all opioids dispensed for every non-overlapped 30-day period from the index date at the individual patient level and divided each by 30 days to obtain the mean daily MME.</p><p id="p0075">We modeled the MMEs over time at monthly intervals. The primary covariate was time, defined as the relative time span over which opioid prescriptions were monitored. We incorporated stimulant prescriptions as a time-varying covariate to control for potential confounding factors that could influence the trajectories. At each time step, we calculated the cumulative number of stimulant prescriptions, spanning from one year before the index date up to that time step, and treated it as a time-varying covariate.</p></sec><sec id="sec2.4"><title>Cohort characteristics</title><p id="p0080">We explored cohort characteristics to investigate their associations with opioid dose trajectory groups. Demographic characteristics included age on the index date, sex, and region. We used patients' regional information to compare opioid prescribing practices by region, grouped into four major regions: Northeast, North Central, South, and West.</p><p id="p0085">Characteristics related to opioid dispensing included the number of opioid prescriptions, the Avg MME, and the Total MME. The number of opioid prescriptions was defined as the number of months in which opioids were dispensed over the study period, with mean and median values calculated across all patients. The Avg MME was defined as the average of the mean daily MMEs for months in which opioids were dispensed, and the Total MME was computed as the sum of all the mean daily MMEs. For a stimulant characteristic, we assessed the total number of stimulant prescriptions each patient received from their first to last opioid prescription dates.</p><p id="p0090">Comorbidities were also assessed as the cohort characteristics, as several studies have suggested a recent increase in stimulant prescriptions that overlap with opioid prescriptions, which is often related to treating attention deficit hyperactivity disorder (ADHD), depression, and other comorbidities in opioid use disorder (OUD) patients or chronic pain in attention deficit hyperactivity disorder patients.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The comorbidities included attention deficit hyperactivity disorder, mental health disorders, such as depression, anxiety, schizophrenia/psychoses, and bipolar, and substance use disorders, involving opioid, tobacco, alcohol, cannabis, and other substances. All comorbidities were identified using ICD-9/10 codes (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S2</xref>) at two different times: after the index date and within one year prior to the index date.</p></sec><sec id="sec2.5"><title>Opioid trajectory modeling</title><p id="p0095">We employed grouped-based trajectory modeling (GBTM)<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> to identify multiple distinct longitudinal trajectories of opioid prescription dosage over time and classify the cohort into trajectory groups. We analyzed the trajectories of monthly opioid doses over a 9-year period after cohort entry. A variety of model configurations were explored, with the best model selected using the Bayesian information criterion (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S12</xref>).</p></sec><sec id="sec2.6"><title>Statistical analysis of covariates</title><p id="p0100">Patient groups by region, gender, stimulant prescriptions, and trajectory groups were compared statistically using Kruskal&#8211;Wallis and Mann&#8211;Whitney U tests, with significance defined as <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05. The characteristics compared included age, the number of opioid prescriptions, the Avg MME, and the Total MME.</p><p id="p0105">We employed a multivariate logistic regression model estimating trajectory membership to compute odds ratios (OR) between different trajectory groups,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> evaluating factors associated with each group based on patient demographics, comorbidities within one year prior to the index date, and stimulant prescription characteristics.</p><p id="p0110">Detailed descriptions of the methods, including study variables, trajectory modeling, and statistical analyses, are provided in the <xref rid="appsec1" ref-type="sec">Supplementary Methods</xref>. Statistical analyses were performed using the SciPy package in Python (version 3.9.7). We followed STROBE reporting guidelines (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S13</xref>).</p></sec><sec id="sec2.7"><title>Ethics committee approval</title><p id="p0115">This study used secondary, de-identified data and was therefore exempt from ethics committee approval.</p></sec><sec id="sec2.8"><title>Role of the funding source</title><p id="p0120">Funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Descriptive summary of study cohort and geographical variations of opioid prescriptions</title><p id="p0125">From an initial cohort of 22,586,656 patients, we developed a study cohort with 2,895,960 patients (<xref rid="tbl1" ref-type="table">Table&#160;1</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Figures&#160;S2 and S3</xref>). The cohort selection pipeline is summarized in <xref rid="appsec1" ref-type="sec">Supplementary Figure&#160;S1</xref>. The average length of follow-up for all patients was 1277 days (standard deviation [SD]: 879). The median age at the index date was 46 years (interquartile range [IQR] 34&#8211;55). The median number of opioid prescriptions was 3, and the Avg MME had a median of 5.42. We observed a higher proportion of comorbidities following opioid exposure compared to before exposure. Notably, the percentage for opioid use disorder after the index date was 5 times higher (0.2% vs 1.1%), and the percentages for mental health disorders as well as other substance use disorders were more than twice as high.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;1</label><caption><p>Summary statistics of the study cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Measure</th><th colspan="1" rowspan="1">Value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Demographics</td><td colspan="1" rowspan="1">Patient No</td><td colspan="1" rowspan="1">2,895,960</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Female (%)</td><td colspan="1" rowspan="1">1,651,883 (57.0)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Male (%)</td><td colspan="1" rowspan="1">1,244,077 (43.0)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Age, median</td><td colspan="1" rowspan="1">46 (34&#8211;55)</td></tr><tr><td colspan="1" rowspan="1">Opioid Prsc</td><td colspan="1" rowspan="1">Prsc No, mean</td><td colspan="1" rowspan="1">4.01 (5.82)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Prsc No, median</td><td colspan="1" rowspan="1">3 (2&#8211;4)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Avg MME, mean</td><td colspan="1" rowspan="1">9.80 (16.73)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Avg MME, median</td><td colspan="1" rowspan="1">5.416 (3.58&#8211;9.17)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Total MME, mean</td><td colspan="1" rowspan="1">57.13 (278.89)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Total MME, median</td><td colspan="1" rowspan="1">15 (8.83&#8211;31.66)</td></tr><tr><td colspan="1" rowspan="1">Stimulant Prsc</td><td colspan="1" rowspan="1">Patient<xref rid="tbl1fna" ref-type="table-fn">a</xref> No (%)</td><td colspan="1" rowspan="1">160,243 (5.5)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Prsc No<xref rid="tbl1fnb" ref-type="table-fn">b</xref>, mean</td><td colspan="1" rowspan="1">12.44 (16.28)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Prsc No, median</td><td colspan="1" rowspan="1">6 (2&#8211;16)</td></tr><tr><td colspan="1" rowspan="1">Comorbidities<xref rid="tbl1fnc" ref-type="table-fn">c</xref></td><td colspan="1" rowspan="1">Depression (%)</td><td colspan="1" rowspan="1">281,463 (9.7)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Anxiety</td><td colspan="1" rowspan="1">352,879 (12.2)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Bipolar</td><td colspan="1" rowspan="1">56,612 (1.9)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Schizophrenia/Psychoses</td><td colspan="1" rowspan="1">7668 (0.3)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Chronic Acute Pain</td><td colspan="1" rowspan="1">1,669,571 (57.7)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">ADHD</td><td colspan="1" rowspan="1">76,217 (2.6)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid overdose</td><td colspan="1" rowspan="1">785 (0.03)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid use disorder</td><td colspan="1" rowspan="1">6397 (0.2)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Tobacco use disorder</td><td colspan="1" rowspan="1">180,710 (6.2)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Alcohol use disorder</td><td colspan="1" rowspan="1">33,638 (1.2)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Cannabis use disorder</td><td colspan="1" rowspan="1">9939 (0.3)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Other substance use disorder</td><td colspan="1" rowspan="1">12,983 (0.4)</td></tr><tr><td colspan="1" rowspan="1">Comorbidities<xref rid="tbl1fnd" ref-type="table-fn">d</xref></td><td colspan="1" rowspan="1">Depression (%)</td><td colspan="1" rowspan="1">591,356 (20.4)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Anxiety</td><td colspan="1" rowspan="1">881,093 (30.4)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Bipolar</td><td colspan="1" rowspan="1">142,969 (4.9)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Schizophrenia/Psychoses</td><td colspan="1" rowspan="1">18,992 (0.7)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Chronic Acute Pain</td><td colspan="1" rowspan="1">2,325,814 (80.3)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">ADHD</td><td colspan="1" rowspan="1">136,857 (4.7)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid overdose</td><td colspan="1" rowspan="1">5280 (0.2)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid use disorder</td><td colspan="1" rowspan="1">31,597 (1.1)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Tobacco use disorder</td><td colspan="1" rowspan="1">372,575 (12.9)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Alcohol use disorder</td><td colspan="1" rowspan="1">90,460 (3.1)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Cannabis use disorder</td><td colspan="1" rowspan="1">33,543 (1.2)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Other substance use disorder</td><td colspan="1" rowspan="1">42,070 (1.5)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are n (%), median (IQR), or mean (SD). No&#160;=&#160;number, Prsc&#160;=&#160;prescription, IQR&#160;=&#160;interquartile range, Avg MME&#160;=&#160;the average of the mean daily MMEs for months in which opioids were dispensed, Total MME&#160;=&#160;the sum of all the mean daily MMEs, ADHD&#160;=&#160;Attention-deficit/hyperactivity disorder.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0015">Patients with stimulant prescriptions were identified based on whether they were prescribed stimulants at any time between the start and end dates of their opioid prescriptions.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0020">Stimulant Prsc No was measured between the start and end dates of opioid prescriptions for each individual patient.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnc"><label>c</label><p id="ntpara0025">Comorbidities were assessed within one year prior to the index date.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnd"><label>d</label><p id="ntpara0030">Comorbidities were assessed after the index date.</p></fn></table-wrap-foot></table-wrap></p><p id="p0130">Significant variation in opioid prescription dosage and numbers was identified among four U.S. regions: South, North Central, West, and Northeast (<xref rid="tbl2" ref-type="table">Table&#160;2</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S3</xref>). Both the South and the West groups had higher Total MME values of 59.31 and 62.66, respectively, compared to the overall study cohort, as well as the Northeast and North Central. The South showed the lowest Avg MME of 8.99 but the highest number of opioid prescriptions of 4.19. In contrast, the West had the highest Avg MME of 12.93, but its number of opioid prescriptions at 3.80 was below the overall average. The South included the highest percentage of patients with stimulant prescriptions at 6.2% (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S3</xref>). The results of statistical tests comparing regions are presented in <xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S11</xref>.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p>Comparison of patient subgroups by region, gender, and stimulant prescriptions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="4" rowspan="1">Region<hr/></th><th colspan="3" rowspan="1">Gender<hr/></th><th colspan="3" rowspan="1">Stimulant Prsc<xref rid="tbl2fna" ref-type="table-fn">a</xref><hr/></th></tr><tr><th colspan="1" rowspan="1">Northeast</th><th colspan="1" rowspan="1">North Central</th><th colspan="1" rowspan="1">South</th><th colspan="1" rowspan="1">West</th><th colspan="1" rowspan="1">Male</th><th colspan="1" rowspan="1">Female</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value<xref rid="tbl2fnc" ref-type="table-fn">c</xref></th><th colspan="1" rowspan="1">w/o STM</th><th colspan="1" rowspan="1">w/STM</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value<xref rid="tbl2fnc" ref-type="table-fn">c</xref></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Demographics</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Patient No (%)</td><td align="char" colspan="1" rowspan="1">370,408 (12.8)</td><td align="char" colspan="1" rowspan="1">584,685 (20.2)</td><td align="char" colspan="1" rowspan="1">1,440,593 (49.7)</td><td align="char" colspan="1" rowspan="1">469,963 (16.2)</td><td align="char" colspan="1" rowspan="1">1,244,077 (43.0)</td><td align="char" colspan="1" rowspan="1">1,651,883 (57.0)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">2,735,717 (94.5)</td><td align="char" colspan="1" rowspan="1">160,243 (5.5)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Age, mean</td><td align="char" colspan="1" rowspan="1">44.63 (13.04)</td><td align="char" colspan="1" rowspan="1">44.01 (13.28)</td><td align="char" colspan="1" rowspan="1">43.79 (12.84)</td><td align="char" colspan="1" rowspan="1">43.55 (13.09)</td><td align="char" colspan="1" rowspan="1">45.08 (12.89)</td><td align="char" colspan="1" rowspan="1">43.04 (13.02)</td><td colspan="1" rowspan="1">&lt;0.0001</td><td align="char" colspan="1" rowspan="1">44.22 (12.95)</td><td align="char" colspan="1" rowspan="1">38.76 (12.82)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"><bold>Opioid Prsc</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Prsc No (%)</td><td align="char" colspan="1" rowspan="1">3.70 (5.06)</td><td align="char" colspan="1" rowspan="1">3.95 (5.47)</td><td align="char" colspan="1" rowspan="1">4.19 (6.38)</td><td align="char" colspan="1" rowspan="1">3.80 (5.03)</td><td align="char" colspan="1" rowspan="1">4.08 (6.08)</td><td align="char" colspan="1" rowspan="1">3.96 (5.63)</td><td colspan="1" rowspan="1">&lt;0.0001</td><td align="char" colspan="1" rowspan="1">3.92 (5.58)</td><td align="char" colspan="1" rowspan="1">5.55 (8.86)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Avg MME, mean</td><td align="char" colspan="1" rowspan="1">9.23 (15.97)</td><td align="char" colspan="1" rowspan="1">9.52 (15.42)</td><td align="char" colspan="1" rowspan="1">8.99 (15.03)</td><td align="char" colspan="1" rowspan="1">12.93 (22.31)</td><td align="char" colspan="1" rowspan="1">10.60 (17.91)</td><td align="char" colspan="1" rowspan="1">9.19 (15.75)</td><td colspan="1" rowspan="1">&lt;0.0001</td><td align="char" colspan="1" rowspan="1">9.73 (16.61)</td><td align="char" colspan="1" rowspan="1">10.90 (18.56)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1">&#160;Total MME, mean</td><td align="char" colspan="1" rowspan="1">50.49 (255.25)</td><td align="char" colspan="1" rowspan="1">50.18 (216.05)</td><td align="char" colspan="1" rowspan="1">59.31 (312.02)</td><td align="char" colspan="1" rowspan="1">62.66 (256.99)</td><td align="char" colspan="1" rowspan="1">64.11 (307.66)</td><td align="char" colspan="1" rowspan="1">51.87 (254.96)</td><td colspan="1" rowspan="1">&lt;0.0001</td><td align="char" colspan="1" rowspan="1">54.51 (264.47)</td><td align="char" colspan="1" rowspan="1">101.78 (457.67)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"><bold>Comorbidities</bold><xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Depression (%)</td><td align="char" colspan="1" rowspan="1">72,684 (19.6)</td><td align="char" colspan="1" rowspan="1">130,081 (22.2)</td><td align="char" colspan="1" rowspan="1">290,205 (20.1)</td><td align="char" colspan="1" rowspan="1">93,154 (19.8)</td><td align="char" colspan="1" rowspan="1">168,248 (13.5)</td><td align="char" colspan="1" rowspan="1">423,108 (25.6)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">521,355 (19.1)</td><td align="char" colspan="1" rowspan="1">70,001 (43.7)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Anxiety</td><td align="char" colspan="1" rowspan="1">117,600 (31.7)</td><td align="char" colspan="1" rowspan="1">181,026 (31.0)</td><td align="char" colspan="1" rowspan="1">445,309 (30.9)</td><td align="char" colspan="1" rowspan="1">131,572 (28.0)</td><td align="char" colspan="1" rowspan="1">277,903 (22.3)</td><td align="char" colspan="1" rowspan="1">603,190 (36.5)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">791,531 (28.9)</td><td align="char" colspan="1" rowspan="1">89,562 (55.9)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Bipolar</td><td align="char" colspan="1" rowspan="1">21,112 (5.7)</td><td align="char" colspan="1" rowspan="1">31,145 (5.3)</td><td align="char" colspan="1" rowspan="1">67,851 (4.7)</td><td align="char" colspan="1" rowspan="1">21,875 (4.7)</td><td align="char" colspan="1" rowspan="1">45,610 (3.7)</td><td align="char" colspan="1" rowspan="1">97,359 (5.9)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">118,157 (4.3)</td><td align="char" colspan="1" rowspan="1">24,812 (15.5)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Schizophrenia</td><td align="char" colspan="1" rowspan="1">2854 (0.8)</td><td align="char" colspan="1" rowspan="1">4086 (0.7)</td><td align="char" colspan="1" rowspan="1">8783 (0.6)</td><td align="char" colspan="1" rowspan="1">3088 (0.7)</td><td align="char" colspan="1" rowspan="1">8389 (0.7)</td><td align="char" colspan="1" rowspan="1">10,603 (0.6)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">16,387 (0.6)</td><td align="char" colspan="1" rowspan="1">2605 (1.6)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic Pain</td><td align="char" colspan="1" rowspan="1">304,849 (82.3)</td><td align="char" colspan="1" rowspan="1">476,720 (81.5)</td><td align="char" colspan="1" rowspan="1">1,152,298 (80.0)</td><td align="char" colspan="1" rowspan="1">369,144 (78.5)</td><td align="char" colspan="1" rowspan="1">991,176 (79.7)</td><td align="char" colspan="1" rowspan="1">1,334,638 (80.8)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">2,188,539 (80.0)</td><td align="char" colspan="1" rowspan="1">137,275 (85.7)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;ADHD</td><td align="char" colspan="1" rowspan="1">14,867 (4.0)</td><td align="char" colspan="1" rowspan="1">26,438 (4.5)</td><td align="char" colspan="1" rowspan="1">76,764 (5.3)</td><td align="char" colspan="1" rowspan="1">17,640 (3.8)</td><td align="char" colspan="1" rowspan="1">54,732 (4.4)</td><td align="char" colspan="1" rowspan="1">82,125 (5.0)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">42,838 (1.6)</td><td align="char" colspan="1" rowspan="1">94,019 (58.7)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Opioid overdose</td><td align="char" colspan="1" rowspan="1">641 (0.2)</td><td align="char" colspan="1" rowspan="1">1204 (0.2)</td><td align="char" colspan="1" rowspan="1">2573 (0.2)</td><td align="char" colspan="1" rowspan="1">831 (0.2)</td><td align="char" colspan="1" rowspan="1">2214 (0.2)</td><td align="char" colspan="1" rowspan="1">3066 (0.2)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">4679 (0.2)</td><td align="char" colspan="1" rowspan="1">601 (0.4)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;OUD</td><td align="char" colspan="1" rowspan="1">4621 (1.2)</td><td align="char" colspan="1" rowspan="1">5092 (0.9)</td><td align="char" colspan="1" rowspan="1">17,333 (1.2)</td><td align="char" colspan="1" rowspan="1">4301 (0.9)</td><td align="char" colspan="1" rowspan="1">15,717 (1.3)</td><td align="char" colspan="1" rowspan="1">15,880 (1.0)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">27,306 (1.0)</td><td align="char" colspan="1" rowspan="1">4291 (2.7)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;TUD</td><td align="char" colspan="1" rowspan="1">47,951 (12.9)</td><td align="char" colspan="1" rowspan="1">92,296 (15.8)</td><td align="char" colspan="1" rowspan="1">187,157 (13.0)</td><td align="char" colspan="1" rowspan="1">41,374 (8.8)</td><td align="char" colspan="1" rowspan="1">189,768 (15.3)</td><td align="char" colspan="1" rowspan="1">182,807 (11.1)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">347,642 (12.7)</td><td align="char" colspan="1" rowspan="1">24,933 (15.6)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;AUD</td><td align="char" colspan="1" rowspan="1">14,689 (4.0)</td><td align="char" colspan="1" rowspan="1">20,840 (3.6)</td><td align="char" colspan="1" rowspan="1">38,883 (2.7)</td><td align="char" colspan="1" rowspan="1">15,480 (3.3)</td><td align="char" colspan="1" rowspan="1">54,955 (4.4)</td><td align="char" colspan="1" rowspan="1">35,505 (2.1)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">81,880 (3.0)</td><td align="char" colspan="1" rowspan="1">8580 (5.4)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;CUD</td><td align="char" colspan="1" rowspan="1">5007 (1.4)</td><td align="char" colspan="1" rowspan="1">9198 (1.6)</td><td align="char" colspan="1" rowspan="1">13,343 (0.9)</td><td align="char" colspan="1" rowspan="1">5841 (1.2)</td><td align="char" colspan="1" rowspan="1">19,095 (1.5)</td><td align="char" colspan="1" rowspan="1">14,448 (0.9)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">29,305 (1.1)</td><td align="char" colspan="1" rowspan="1">4238 (2.6)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Other SUD</td><td align="char" colspan="1" rowspan="1">6541 (1.8)</td><td align="char" colspan="1" rowspan="1">7841 (1.3)</td><td align="char" colspan="1" rowspan="1">21,079 (1.5)</td><td align="char" colspan="1" rowspan="1">6248 (1.3)</td><td align="char" colspan="1" rowspan="1">21,565 (1.7)</td><td align="char" colspan="1" rowspan="1">20,505 (1.2)</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">35,525 (1.3)</td><td align="char" colspan="1" rowspan="1">6545 (4.1)</td><td colspan="1" rowspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><fn><p>Data are n (%) or mean (SD). No&#160;=&#160;number, Prsc&#160;=&#160;prescription, w/o STM&#160;=&#160;patients without stimulant prescriptions, w/STM&#160;=&#160;patients with stimulant prescriptions, Avg MME&#160;=&#160;the average of the mean daily MMEs for months in which opioids were dispensed, Total MME&#160;=&#160;the sum of all the mean daily MMEs, ADHD&#160;=&#160;Attention-deficit/hyperactivity disorder, OUD&#160;=&#160;opioid use disorder, TUD&#160;=&#160;tobacco use disorder, AUD&#160;=&#160;alcohol use disorder, CUD&#160;=&#160;cannabis use disorder, SUD&#160;=&#160;substance use disorder.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0035">Patients with stimulant prescriptions were identified based on whether they were prescribed stimulants at any time between the start and end dates of their opioid prescriptions.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0040">Comorbidities were assessed after the index date.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnc"><label>c</label><p id="ntpara0045">Mann-Whitney U tests were performed to compare patient subgroups by gender and stimulant prescriptions.</p></fn></table-wrap-foot></table-wrap></p><p id="p0135">When we compared gender groups (<xref rid="tbl2" ref-type="table">Table&#160;2</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S10</xref>), males were older than females, with mean ages of 45.1 and 43.0, respectively, and had higher opioid doses, with the Avg MME values of 10.60 and 9.19, and the Total MME values of 64.11 and 51.87, respectively.</p></sec><sec id="sec3.2"><title>Model 1: opioid dose trajectory baseline model</title><p id="p0140">We identified five distinct trajectories of opioid dosage during 108 months from the opioid baseline model without the stimulant covariate (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>(a) and <xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S4</xref>): very low-dose (2,243,167 patients, 77.5%) with a median of 4.5 Avg MME (IQR 3.3&#8211;6.3), low-dose decreasing (204,607, 7.0%) with 14.3 (IQR 11.2&#8211;21.7), low-dose increasing (335,266, 11.6%) with 14.6 (IQR 11.9&#8211;18.8), moderate-dose increasing (68,504, 2.4%) with 43.8 (IQR 36.1&#8211;55.4), and high-dose sustained use (44,416, 1.5%) with 104.1 (IQR 84.2&#8211;137.5).<fig id="fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Trajectories of opioid doses from (a) the opioid baseline model and (b) the opioid-stimulant model. &#8727;The figure shows trajectories of the mean daily MME over 9 years. The shaded areas show 99% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0145">The very low-dose and high-dose sustained use groups exhibited the largest differences in opioid-related characteristics. The differences were 3-fold for the mean number of opioid prescriptions, with 3.21 in the very low-dose group and 9.66 in the high-dose sustained use group, 23-fold for the Avg MME, with 4.91 and 115.43, and about 54-fold for the Total MME, with 16.40 and 884.60, respectively (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S4</xref>).</p></sec><sec id="sec3.3"><title>Model 2: the associations between stimulant prescriptions and opioid dose trajectories</title><p id="p0150">We obtained patients with stimulant prescriptions who were prescribed stimulants at any point between their first and last opioid prescription dates, totaling 160,243 (5.5%) patients with a median of 6 stimulant prescriptions (IQR 2&#8211;16). Patients with stimulant prescriptions were younger than those without, with mean ages of 38.8 and 44.2 years, respectively, and had more opioid prescriptions and higher opioid doses, with mean numbers of opioid prescriptions of 5.55 and 3.92, and the mean Avg MME values of 10.90 and 9.73 (<xref rid="tbl2" ref-type="table">Table&#160;2</xref>). The mean Total MME was twice as high in the group with stimulant prescriptions, at 101.78 compared to 54.51. Additionally, the stimulant group had a heavier burden of comorbidities after the index date than those without stimulant prescriptions.</p><p id="p0155">Stimulant prescriptions were included in the opioid trajectory model as a time-varying covariate to evaluate the relationship between stimulant prescriptions and opioid dose trajectories (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>(b) and <xref rid="tbl3" ref-type="table">Table&#160;3</xref>). Trajectory groups were named based on observed dosage trends in <xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>(b) as &#8216;very low,&#8217; &#8216;low-dose increasing,&#8217; &#8216;low-dose decreasing,&#8217; &#8216;moderate-dose increasing,&#8217; and &#8216;high-dose sustained.&#8217; We observed shifted patient group memberships for the opioid-stimulant model compared to the opioid baseline model.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table&#160;3</label><caption><p>Descriptive characteristics by trajectory groups from the opioid-stimulant model.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th rowspan="2" colspan="1">Measure</th><th rowspan="2" colspan="1">Very low-dose</th><th colspan="1" rowspan="1">Low-dose<hr/></th><th colspan="1" rowspan="1">Low-dose<hr/></th><th colspan="1" rowspan="1">Moderate-dose<hr/></th><th colspan="1" rowspan="1">High-dose<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> value<xref rid="tbl3fne" ref-type="table-fn">e</xref></th></tr><tr><th colspan="1" rowspan="1">Decreasing</th><th colspan="1" rowspan="1">Increasing</th><th colspan="1" rowspan="1">Increasing</th><th colspan="1" rowspan="1">Sustained use</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Demographics</bold></td><td colspan="1" rowspan="1">Patient No (%)</td><td align="char" colspan="1" rowspan="1">2,245,684 (77.5)</td><td align="char" colspan="1" rowspan="1">295,527 (10.2)</td><td align="char" colspan="1" rowspan="1">245,072 (8.5)</td><td align="char" colspan="1" rowspan="1">68,248 (2.4)</td><td align="char" colspan="1" rowspan="1">41,429 (1.4)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Female (%)</td><td align="char" colspan="1" rowspan="1">1,322,171 (58.9)</td><td align="char" colspan="1" rowspan="1">151,186 (51.2)</td><td align="char" colspan="1" rowspan="1">122,151 (49.8)</td><td align="char" colspan="1" rowspan="1">35,311 (51.7)</td><td align="char" colspan="1" rowspan="1">21,064 (50.8)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Age, median</td><td align="char" colspan="1" rowspan="1">44 (33&#8211;54)</td><td align="char" colspan="1" rowspan="1">50 (39&#8211;57)</td><td align="char" colspan="1" rowspan="1">50 (39&#8211;58)</td><td align="char" colspan="1" rowspan="1">48 (37&#8211;57)</td><td align="char" colspan="1" rowspan="1">49 (38&#8211;56)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"><bold>Opioid Prsc</bold></td><td colspan="1" rowspan="1">Prsc No, mean</td><td align="char" colspan="1" rowspan="1">3.15 (2.55)</td><td align="char" colspan="1" rowspan="1">6.34 (8.04)</td><td align="char" colspan="1" rowspan="1">6.40 (8.28)</td><td align="char" colspan="1" rowspan="1">10.30 (16.39)</td><td align="char" colspan="1" rowspan="1">9.92 (15.11)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Prsc No, median</td><td align="char" colspan="1" rowspan="1">2 (2&#8211;3)</td><td align="char" colspan="1" rowspan="1">4 (3&#8211;7)</td><td align="char" colspan="1" rowspan="1">3 (2&#8211;5)</td><td align="char" colspan="1" rowspan="1">3 (2&#8211;10)</td><td align="char" colspan="1" rowspan="1">4 (2&#8211;9)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Avg MME, mean</td><td align="char" colspan="1" rowspan="1">4.93 (2.26)</td><td align="char" colspan="1" rowspan="1">15.33 (6.67)</td><td align="char" colspan="1" rowspan="1">18.04 (8.43)</td><td align="char" colspan="1" rowspan="1">51.68 (14.12)</td><td align="char" colspan="1" rowspan="1">116.08 (42.79)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Avg MME, median</td><td align="char" colspan="1" rowspan="1">4.55 (3.25&#8211;6.25)</td><td align="char" colspan="1" rowspan="1">12.77 (10.66&#8211;17.5)</td><td align="char" colspan="1" rowspan="1">16.5 (13.33&#8211;21.52)</td><td align="char" colspan="1" rowspan="1">48.55 (40&#8211;60.83)</td><td align="char" colspan="1" rowspan="1">108.3 (83.33&#8211;141.6)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Total MME, mean</td><td align="char" colspan="1" rowspan="1">15.96 (20.42)</td><td align="char" colspan="1" rowspan="1">91.16 (136.83)</td><td align="char" colspan="1" rowspan="1">129.71 (186.81)</td><td align="char" colspan="1" rowspan="1">489.84 (741.76)</td><td align="char" colspan="1" rowspan="1">904.02 (1494.84)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Total MME, median</td><td align="char" colspan="1" rowspan="1">12 (7.67&#8211;18.66)</td><td align="char" colspan="1" rowspan="1">56.66 (35.26&#8211;99.16)</td><td align="char" colspan="1" rowspan="1">50 (32.5&#8211;90.5)</td><td align="char" colspan="1" rowspan="1">168.3 (107.5&#8211;435)</td><td align="char" colspan="1" rowspan="1">335.8 (228.7&#8211;708.3)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"><bold>Stimulant Prsc</bold></td><td colspan="1" rowspan="1">Patient<xref rid="tbl3fna" ref-type="table-fn">a</xref> No (%)</td><td align="char" colspan="1" rowspan="1">111,087 (4.9)</td><td align="char" colspan="1" rowspan="1">14,793 (5.0)</td><td align="char" colspan="1" rowspan="1">23,616 (9.6)</td><td align="char" colspan="1" rowspan="1">6681 (9.8)</td><td align="char" colspan="1" rowspan="1">4066 (9.8)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Prsc No<xref rid="tbl3fnb" ref-type="table-fn">b</xref>, mean</td><td align="char" colspan="1" rowspan="1">12.33 (16.94)</td><td align="char" colspan="1" rowspan="1">15.70 (18.50)</td><td align="char" colspan="1" rowspan="1">10.88 (16.22)</td><td align="char" colspan="1" rowspan="1">12.19 (15.89)</td><td align="char" colspan="1" rowspan="1">13.01 (17.97)</td><td colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Prsc No, median</td><td align="char" colspan="1" rowspan="1">6 (2&#8211;16)</td><td align="char" colspan="1" rowspan="1">8 (3&#8211;21)</td><td align="char" colspan="1" rowspan="1">5 (2&#8211;14)</td><td align="char" colspan="1" rowspan="1">6 (2&#8211;15)</td><td align="char" colspan="1" rowspan="1">7 (2&#8211;16)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"><bold>Comorbidities</bold><xref rid="tbl3fnc" ref-type="table-fn">c</xref></td><td colspan="1" rowspan="1">Depression (%)</td><td align="char" colspan="1" rowspan="1">202,919 (9.0)</td><td align="char" colspan="1" rowspan="1">32,545 (11.0)</td><td align="char" colspan="1" rowspan="1">29,636 (12.1)</td><td align="char" colspan="1" rowspan="1">10,040 (14.7)</td><td align="char" colspan="1" rowspan="1">6323 (15.3)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Anxiety</td><td align="char" colspan="1" rowspan="1">265,442 (11.8)</td><td align="char" colspan="1" rowspan="1">36,079 (12.2)</td><td align="char" colspan="1" rowspan="1">33,912 (13.8)</td><td align="char" colspan="1" rowspan="1">10,993 (16.1)</td><td align="char" colspan="1" rowspan="1">6453 (15.6)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Bipolar</td><td align="char" colspan="1" rowspan="1">41,772 (1.9)</td><td align="char" colspan="1" rowspan="1">6010 (2.0)</td><td align="char" colspan="1" rowspan="1">5744 (2.3)</td><td align="char" colspan="1" rowspan="1">1924 (2.8)</td><td align="char" colspan="1" rowspan="1">1162 (2.8)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Schizophrenia/Psychoses</td><td align="char" colspan="1" rowspan="1">5363 (0.2)</td><td align="char" colspan="1" rowspan="1">885 (0.3)</td><td align="char" colspan="1" rowspan="1">910 (0.4)</td><td align="char" colspan="1" rowspan="1">287 (0.4)</td><td align="char" colspan="1" rowspan="1">223 (0.5)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Chronic Acute Pain</td><td align="char" colspan="1" rowspan="1">1,187,764 (52.9)</td><td align="char" colspan="1" rowspan="1">216,649 (73.3)</td><td align="char" colspan="1" rowspan="1">186,744 (76.2)</td><td align="char" colspan="1" rowspan="1">48,310 (70.8)</td><td align="char" colspan="1" rowspan="1">30,104 (72.7)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">ADHD</td><td align="char" colspan="1" rowspan="1">56,259 (2.5)</td><td align="char" colspan="1" rowspan="1">5908 (2.0)</td><td align="char" colspan="1" rowspan="1">10,181 (4.2)</td><td align="char" colspan="1" rowspan="1">2611 (3.8)</td><td align="char" colspan="1" rowspan="1">1258 (3.0)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid overdose</td><td align="char" colspan="1" rowspan="1">501 (0.02)</td><td align="char" colspan="1" rowspan="1">100 (0.03)</td><td align="char" colspan="1" rowspan="1">99 (0.04)</td><td align="char" colspan="1" rowspan="1">52 (0.08)</td><td align="char" colspan="1" rowspan="1">33 (0.08)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid use disorder</td><td align="char" colspan="1" rowspan="1">3080 (0.1)</td><td align="char" colspan="1" rowspan="1">758 (0.3)</td><td align="char" colspan="1" rowspan="1">1194 (0.5)</td><td align="char" colspan="1" rowspan="1">833 (1.2)</td><td align="char" colspan="1" rowspan="1">532 (1.3)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Tobacco use disorder</td><td align="char" colspan="1" rowspan="1">129,032 (5.8)</td><td align="char" colspan="1" rowspan="1">21,780 (7.4)</td><td align="char" colspan="1" rowspan="1">19,272 (7.9)</td><td align="char" colspan="1" rowspan="1">6555 (9.6)</td><td align="char" colspan="1" rowspan="1">4071 (9.8)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Alcohol use disorder</td><td align="char" colspan="1" rowspan="1">22,534 (1.0)</td><td align="char" colspan="1" rowspan="1">4583 (1.6)</td><td align="char" colspan="1" rowspan="1">4409 (1.8)</td><td align="char" colspan="1" rowspan="1">1325 (1.9)</td><td align="char" colspan="1" rowspan="1">787 (1.9)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Cannabis use disorder</td><td align="char" colspan="1" rowspan="1">7533 (0.3)</td><td align="char" colspan="1" rowspan="1">949 (0.3)</td><td align="char" colspan="1" rowspan="1">920 (0.4)</td><td align="char" colspan="1" rowspan="1">338 (0.5)</td><td align="char" colspan="1" rowspan="1">199 (0.5)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Other substance use disorder</td><td align="char" colspan="1" rowspan="1">8350 (0.4)</td><td align="char" colspan="1" rowspan="1">1569 (0.5)</td><td align="char" colspan="1" rowspan="1">1636 (0.7)</td><td align="char" colspan="1" rowspan="1">831 (1.2)</td><td align="char" colspan="1" rowspan="1">597 (1.4)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"><bold>Comorbidities</bold><xref rid="tbl3fnd" ref-type="table-fn">d</xref></td><td colspan="1" rowspan="1">Depression (%)</td><td align="char" colspan="1" rowspan="1">433,467 (19.3)</td><td align="char" colspan="1" rowspan="1">75,912 (25.7)</td><td align="char" colspan="1" rowspan="1">52,576 (21.5)</td><td align="char" colspan="1" rowspan="1">17,744 (26.0)</td><td align="char" colspan="1" rowspan="1">11,657 (28.1)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Anxiety</td><td align="char" colspan="1" rowspan="1">670,977 (29.9)</td><td align="char" colspan="1" rowspan="1">104,314 (35.3)</td><td align="char" colspan="1" rowspan="1">69,254 (28.3)</td><td align="char" colspan="1" rowspan="1">22,316 (32.7)</td><td align="char" colspan="1" rowspan="1">14,232 (34.4)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Bipolar</td><td align="char" colspan="1" rowspan="1">106,133 (4.7)</td><td align="char" colspan="1" rowspan="1">18,075 (6.1)</td><td align="char" colspan="1" rowspan="1">12,133 (5.0)</td><td align="char" colspan="1" rowspan="1">3961 (5.8)</td><td align="char" colspan="1" rowspan="1">2667 (6.4)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Schizophrenia/Psychoses</td><td align="char" colspan="1" rowspan="1">13,425 (0.6)</td><td align="char" colspan="1" rowspan="1">2576 (0.9)</td><td align="char" colspan="1" rowspan="1">1861 (0.8)</td><td align="char" colspan="1" rowspan="1">629 (0.9)</td><td align="char" colspan="1" rowspan="1">501 (1.2)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Chronic Acute Pain</td><td align="char" colspan="1" rowspan="1">1,734,406 (77.2)</td><td align="char" colspan="1" rowspan="1">276,009 (93.4)</td><td align="char" colspan="1" rowspan="1">219,610 (89.6)</td><td align="char" colspan="1" rowspan="1">58,738 (86.1)</td><td align="char" colspan="1" rowspan="1">37,051 (89.4)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">ADHD</td><td align="char" colspan="1" rowspan="1">101,355 (4.5)</td><td align="char" colspan="1" rowspan="1">12,337 (4.2)</td><td align="char" colspan="1" rowspan="1">16,583 (6.8)</td><td align="char" colspan="1" rowspan="1">4250 (6.2)</td><td align="char" colspan="1" rowspan="1">2332 (5.6)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid overdose</td><td align="char" colspan="1" rowspan="1">2937 (0.1)</td><td align="char" colspan="1" rowspan="1">1024 (0.3)</td><td align="char" colspan="1" rowspan="1">674 (0.3)</td><td align="char" colspan="1" rowspan="1">361 (0.5)</td><td align="char" colspan="1" rowspan="1">284 (0.7)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Opioid use disorder</td><td align="char" colspan="1" rowspan="1">12,956 (0.6)</td><td align="char" colspan="1" rowspan="1">6113 (2.1)</td><td align="char" colspan="1" rowspan="1">6189 (2.5)</td><td align="char" colspan="1" rowspan="1">3869 (5.7)</td><td align="char" colspan="1" rowspan="1">2470 (6.0)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Tobacco use disorder</td><td align="char" colspan="1" rowspan="1">270,142 (12.0)</td><td align="char" colspan="1" rowspan="1">49,778 (16.8)</td><td align="char" colspan="1" rowspan="1">33,582 (13.7)</td><td align="char" colspan="1" rowspan="1">11,541 (16.9)</td><td align="char" colspan="1" rowspan="1">7532 (18.2)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Alcohol use disorder</td><td align="char" colspan="1" rowspan="1">63,613 (2.8)</td><td align="char" colspan="1" rowspan="1">13,792 (4.7)</td><td align="char" colspan="1" rowspan="1">8619 (3.5)</td><td align="char" colspan="1" rowspan="1">2664 (3.9)</td><td align="char" colspan="1" rowspan="1">1772 (4.3)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Cannabis use disorder</td><td align="char" colspan="1" rowspan="1">25,375 (1.1)</td><td align="char" colspan="1" rowspan="1">4068 (1.4)</td><td align="char" colspan="1" rowspan="1">2566 (1.1)</td><td align="char" colspan="1" rowspan="1">906 (1.3)</td><td align="char" colspan="1" rowspan="1">628 (1.5)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Other SUD</td><td align="char" colspan="1" rowspan="1">26,706 (1.2)</td><td align="char" colspan="1" rowspan="1">6493 (2.2)</td><td align="char" colspan="1" rowspan="1">4791 (2.0)</td><td align="char" colspan="1" rowspan="1">2355 (3.5)</td><td align="char" colspan="1" rowspan="1">1725 (4.2)</td><td colspan="1" rowspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><fn><p>Data are n (%), median (IQR), or mean (SD). Demo&#160;=&#160;demographics, No&#160;=&#160;number, Prsc&#160;=&#160;prescription, IQR&#160;=&#160;interquartile range, STM&#160;=&#160;stimulant, Avg MME&#160;=&#160;the average of all the mean daily MMEs for months in which opioids were dispensed, Total MME&#160;=&#160;the sum of all the mean daily MMEs, ADHD&#160;=&#160;Attention-deficit/hyperactivity disorder, SUD&#160;=&#160;substance use disorder.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0050">Patients with stimulant prescriptions were identified based on whether they were prescribed stimulants at any time between the start and end dates of their opioid prescriptions.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0055">Stimulant Prsc No was measured between the start and end dates of opioid prescriptions for each individual patient.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnc"><label>c</label><p id="ntpara0060">Comorbidities were assessed within one year prior to the index date.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnd"><label>d</label><p id="ntpara0065">Comorbidities were assessed after the index date.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fne"><label>e</label><p id="ntpara0070">Kruskal-Wallis tests were performed to compare all trajectory groups.</p></fn></table-wrap-foot></table-wrap></p><p id="p0160">Among the trajectory groups, patients prescribed stimulants had the highest rates (9.8%) in the moderate-dose increasing and high-dose sustained use groups (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>), followed by the low-dose increasing group (9.6%), which were about twice as high compared to the very low-dose (4.9%) and low-dose decreasing groups (5.0%). These three groups also had higher proportions of patients with attention deficit hyperactivity disorder or substance use disorders. In the group comparative analysis (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>), we focused on the low-dose decreasing and low-dose increasing groups, which initiated opioids at similar doses, to investigate factors associated with the increasing opioid dose trajectory, specifically the impact of stimulant prescriptions on subsequent trajectory patterns. The number of stimulant prescriptions before the index date had a relatively higher odds ratio (OR: 7.58; 95% confidence intervals [CI]: 6.14&#8211;9.35) for being in the increasing group compared to the decreasing group. The time-varying number of simulant prescriptions was also associated with a higher odds ratio (OR: 1.73; 95% CI: 1.40&#8211;2.14).<fig id="fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Distribution plots of odds ratio from a logistic regression model estimating trajectory membership for the low-dose decreasing group (reference) vs the low-dose increasing group to evaluate factors associated with the groups. &#8727;All reported variables were statistically significant with <italic toggle="yes">P</italic>&#160;&lt;&#160;0.01. The comorbidities were assessed within one year prior to the index date. Simulant counts before the index date were measured as the total number of stimulant prescriptions within one year prior to the index date. Simulant counts&#8212;time varying represented the cumulative number of stimulant prescriptions at each monthly interval time step from one year before the index date up to that time step, while Simulant counts&#8212;time varying (binary) represented these counts as binary values (1 if the count is greater than 0, otherwise 0). OR&#160;=&#160;odds ratio, CI&#160;=&#160;confidence interval, ADHD&#160;=&#160;Attention-deficit/hyperactivity disorder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0165">Regional variations were also observed among the identified groups. The moderate-dose increasing and high-dose sustained use groups had higher proportions of patients from the West and fewer from the South compared to the overall study cohort and other groups (<xref rid="appsec1" ref-type="sec">Supplementary Tables&#160;S5&#8211;S9</xref>).</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0170">The so-called twin epidemic has drawn increasing attention in recent years. Despite strict regulations on opioid and stimulant prescriptions, both opioid- and stimulant-related overdose deaths have kept increasing,<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> and the group with co-prescription is at high risk.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref> Studies have suggested that the co-use of opioids and stimulants can synergistically reinforce drug effects and increase the risk of overdose and other adverse health outcomes.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> In this study, we conducted one of the largest analyses to examine the potential associations between opioid and stimulant prescriptions over the recent 10 years across the United States. We utilized MarketScan, one of the largest national claims databases, for cohort development and pattern identification, which has been used in multiple studies to investigate clinical patterns across the country.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> One of the major aims of this study is to provide data-driven evidence on national prescription trends to facilitate future opioid and stimulant prescription guidelines and interventions. Currently, the United States does not restrict central nervous system stimulant prescriptions among patients with substance use disorder or under opioid treatment, while regulation policy has been implemented in some north European countries. For example, Norway has restrictions on prescribing central stimulants to individuals who have substance use disorders or who are on opioid maintenance treatment.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Similar restrictions could be recommended in US healthcare systems. However, more large-scale studies in US patient populations need to be conducted to support adaption of related prescription guidelines.</p><p id="p0175">Our trajectory model identified five distinct opioid dosage trajectories from the model with the stimulant covariate (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>(b) and <xref rid="tbl3" ref-type="table">Table&#160;3</xref>). Adding stimulant co-prescriptions as a time-varying covariate did change the shape of opioid trajectories and patient group memberships, suggesting a correlation between opioid doses and stimulant prescriptions over time. Specifically, with the time-varying stimulant covariate, the proportion of patients with stimulant prescriptions increased in groups showing increasing trends or moderate-to-high opioid doses (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>) compared to the opioid baseline model (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S4</xref>). The proportions in the opioid baseline model vs. the opioid-stimulant model are: very low dose (5.3% vs 4.9%), low-dose decreasing (7.6% vs 5.0%), low-dose increasing (5.1% vs 9.6%), moderate-dose increasing (6.7% vs 9.8%), and high-dose sustained use (7.6% vs 9.8%). In <xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>, the starting points of the low-dose decreasing and low-dose increasing groups differed between the opioid baseline and opioid-stimulant models, suggesting changes in group membership, which align with the observed variations in the proportions of patients with stimulant prescriptions in these groups.</p><p id="p0180">In the opioid-stimulant model (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>), the vast majority of the cohort (77.5%) exhibited very low opioid doses, which is consistent with previous studies.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> The very low-dose group exhibited the lowest percentages of patients with most comorbidities before the index date, while the high-dose sustain use group had the highest percentages. The comorbidities present before initiating opioids appear to be associated with higher opioid doses, indicating that underlying health conditions were potentially leading to subsequent opioid prescribing. With this knowledge, screening for comorbidities at the time of first opioid prescribing and at subsequent visits can be essential in managing opioid prescriptions to prevent escalation to high-dose, and even persistent, opioid use.</p><p id="p0185">Patients who were prescribed stimulants had the highest rates in the moderate-dose increasing and high-dose sustained use groups, followed by the low-dose increasing group. Stimulant prescription appears to be associated with higher or increasing opioid dose groups, indicating relations between these two types of drugs in opioid prescription activities. The finding was further supported by statistical analysis of the study cohort (<xref rid="tbl2" ref-type="table">Table&#160;2</xref>), which showed that patients prescribed stimulants were more frequently prescribed opioids and had higher doses compared to those without stimulant prescriptions. Stimulant use alongside opioids may contribute to higher or elevated dosage patterns, underscoring the need for careful management of these drugs.</p><p id="p0190">We further quantified associations between stimulant and opioid prescriptions. The number of stimulant prescriptions prior to the initial opioid prescription had a relatively higher odds ratio (OR: 7.58, 95% CI: 6.14&#8211;9.35) for being in the low-dose increasing group compared to the decreasing group, which strongly indicates that stimulant prescriptions before initiating opioids are positively associated with escalating opioid doses. The time-varying number of stimulant prescriptions also had a higher odds ratio (OR: 1.73, 95% CI: 1.40&#8211;2.14), suggesting that stimulant co-prescriptions were significantly associated with increasing opioid doses, and this could potentially lead to a higher rate of opioid use disorder. This positive association we identified suggested a persistent driving force to the twin epidemic on a national level.</p><p id="p0195">Our study also revealed gender variations in opioid prescribing practices. Males were prescribed opioids more frequently and at higher doses compared to females. The finding is supported by previous evidence showing that males received higher doses of pain medication among patients with chronic pain,<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> and were more likely to escalate to high-dose opioid therapy than females.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Furthermore, healthcare providers issued fewer prescriptions to females during ambulatory care and outpatient visits.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> The difference in opioid prescribing practices likely reflects underlying gender disparities in the management of medical conditions.</p><p id="p0200">We also observed prescription variations among four U.S. regions. The South and the West regions had higher Total MMEs compared to the overall rate of the country, as well as the Northeast and North Central regions. The West had fewer opioid prescriptions but tended to prescribe more potent opioids per prescription. The finding aligns with the previous research indicating that high-dose initial prescriptions were most common among patients in the West, and long-duration prescriptions were most prevalent in the South.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Another study found that healthcare providers in the Northeast and Midwest were significantly less likely to prescribe opioids than those in the South and West.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Importantly, our study duration was based on recent data, suggesting these regional variations persist in healthcare systems. The regional variations may be influenced by the local social environment, the prescribing practices of providers in the region,<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> and the regulation of healthcare systems. Understanding these regional variations and which approaches achieve better outcomes is crucial for developing future region-specific policies to address the opioid- and twin epidemic more effectively.</p><p id="p0205">This study has several limitations. First, the dataset is de-identified and lacks race information, preventing an analysis of racial differences in opioid prescribing practices. Given the extensive research on racial/ethnic differences in opioid prescribing patterns,<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> especially in pain management within the U.S. health system,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> understanding racial disparities is crucial for addressing inequities in healthcare. Second, the absence of provider and hospital information in our dataset limits our ability to further assess the influence of provider and hospital settings<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> on prescription patterns. Third, co-prescription of these two categories may be clinically indicated in certain patients, so across-the-board bans of co-prescription would not be an effective policy. Fourth, our study was among adults with private health insurance, not covering the population with federal insurance programs, such as Medicaid. This will limit the generalizability of the identified patterns. Lastly, we identified significant associations between opioids and stimulants in this study, while causality and direction of effects cannot be ascertained from the current study design. These limitations highlight areas for future research to provide a more comprehensive understanding of the factors influencing opioid use.</p><p id="p0210">In this large-scale cohort study, we found that stimulant prescriptions had a significant impact on opioid dose trajectories, suggesting a strong association between these two types of drugs across the country. Our results highlight a strong longitudinal association between stimulants and opioids, indicating that stimulant prescriptions were positively associated with increasing opioid prescription dose trajectories. Additionally, our analysis revealed notable gender and regional variations among the four regions of the United States. Our findings suggested that co-prescriptions could serve as a persistent driving force for the twin epidemic in the U.S. healthcare systems over a 10-year period. This evidence needs to be considered in the development of future prescription guidelines and hospital policy.</p></sec><sec id="sec5"><title>Contributors</title><p id="p0215">PZ and WS conceptualized and supervised this study. SL and WS designed the longitudinal cohort study, and PZ accessed, processed, and verified the dataset and methods underlying this study. SL developed the methodology and conducted the data analysis. SL, WS, and PZ wrote the original draft, with critical contributions from DWB and RDU. DWB and RDU provided important clinical guidance. All authors assisted with literature search, data analysis, and data interpretation. All authors from The Ohio State University had full access to all the data in the study. All authors read and approved the final manuscript and had final responsibility for the decision to submit for publication.</p></sec><sec id="sec6"><title>Data sharing statement</title><p id="p0220">The dataset we used is from MarketScan Commercial Claims and Encounters (CCAE, more than 130 million patients from 2012 to 2021), which contains individual-level and de-identified healthcare claims information. Access to the MarketScan data analyzed in this study is provided by The Ohio State University. The dataset is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.merative.com/real-world-evidence" id="intref0010">https://www.merative.com/real-world-evidence</ext-link>.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of interests</title><p id="p0225">DWB reports grants and personal fees from EarlySense, personal fees from CDI Negev, equity from ValeraHealth, equity from Clew, equity from MDClone, personal fees and equity from AESOP, personal fees and equity from FeelBetter, and personal fees and equity from Guided Clinical Solutions, outside the submitted work. RDU serves as a secretary of the Society for Ambulatory Anesthesia (unpaid), a treasurer of the Association of Anesthesia Clinical Directors (unpaid), and a vice president of ERAS USA (unpaid), and reports fees from AcelRx. The other authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Gardner</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>D.</given-names></name></person-group><article-title>The opioid crisis: prevalence and markets of opioids</article-title><source>Forensic Sci Rev</source><volume>34</volume><year>2022</year><fpage>43</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">35105535</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Strickland</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Havens</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Stoops</surname><given-names>W.W.</given-names></name></person-group><article-title>A&#160;nationally representative analysis of &#8220;twin epidemics&#8221;: rising rates of methamphetamine use among persons who use opioids</article-title><source>Drug Alcohol Depend</source><volume>204</volume><year>2019</year><object-id pub-id-type="publisher-id">107592</object-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.107592</pub-id><pub-id pub-id-type="pmcid">PMC6884137</pub-id><pub-id pub-id-type="pmid">31586804</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="book" id="sref3"><person-group person-group-type="author"><collab>U.S. Overdose Deaths Decrease in 2023</collab></person-group><year>2024</year><publisher-name>First Time Since 2018</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm" id="intref0020">https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm</ext-link></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Miano</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Identifying clinically relevant drug&#8211;drug interactions with methadone and buprenorphine: a translational approach to signal detection</article-title><source>Clin Pharmacol Ther</source><volume>112</volume><year>2022</year><fpage>1120</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1002/cpt.2717</pub-id><pub-id pub-id-type="pmid">35881659</pub-id><pub-id pub-id-type="pmcid">PMC10015595</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="book" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Kutscher</surname><given-names>E.</given-names></name></person-group><part-title>Stimulant use disorders in the United States&#8212;is another epidemic on the horizon?</part-title><source>JAMA Health Forum</source><year>2020</year><publisher-name>American Medical Association</publisher-name><fpage>e201486</fpage><pub-id pub-id-type="doi">10.1001/jamahealthforum.2020.1486</pub-id><pub-id pub-id-type="pmid">36218481</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Palis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Association of opioid and stimulant use disorder diagnoses with fatal and nonfatal overdose among people with a history of incarceration</article-title><source>JAMA Netw Open</source><volume>5</volume><year>2022</year><fpage>e2243653</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.43653</pub-id><pub-id pub-id-type="pmid">36416821</pub-id><pub-id pub-id-type="pmcid">PMC9685494</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Post</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Lundberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Geographic trends in opioid overdoses in the US from 1999 to 2020</article-title><source>JAMA Netw Open</source><volume>5</volume><year>2022</year><fpage>e2223631</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.23631</pub-id><pub-id pub-id-type="pmid">35900768</pub-id><pub-id pub-id-type="pmcid">PMC9335141</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Ware</surname><given-names>O.D.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Hobelmann</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Finan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huhn</surname><given-names>A.S.</given-names></name></person-group><article-title>The association of chronic pain and opioid withdrawal in men and women with opioid use disorder</article-title><source>Drug Alcohol Depend</source><volume>240</volume><year>2022</year><object-id pub-id-type="publisher-id">109631</object-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2022.109631</pub-id><pub-id pub-id-type="pmid">36126611</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Compton</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Valentino</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>DuPont</surname><given-names>R.L.</given-names></name></person-group><article-title>Polysubstance use in the US opioid crisis</article-title><source>Mol Psychiatry</source><volume>26</volume><year>2021</year><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/s41380-020-00949-3</pub-id><pub-id pub-id-type="pmid">33188253</pub-id><pub-id pub-id-type="pmcid">PMC7815508</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.-J.J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bussing</surname><given-names>R.</given-names></name><name name-style="western"><surname>Winterstein</surname><given-names>A.G.</given-names></name></person-group><article-title>Prevalence of and factors associated with long-term concurrent use of stimulants and opioids among adults with attention-deficit/hyperactivity disorder</article-title><source>JAMA Netw Open</source><volume>1</volume><year>2018</year><fpage>e181152</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.1152</pub-id><pub-id pub-id-type="pmid">30646105</pub-id><pub-id pub-id-type="pmcid">PMC6324259</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>R.A.</given-names></name></person-group><article-title>The fourth wave of the US opioid epidemic and its implications for the rural US: a federal perspective</article-title><source>Prev Med</source><volume>152</volume><year>2021</year><object-id pub-id-type="publisher-id">106541</object-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106541</pub-id><pub-id pub-id-type="pmid">34482994</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Palis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dobrer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Concurrent use of opioids and&#160;stimulants and risk of fatal overdose: a cohort study</article-title><source>BMC Public Health</source><volume>22</volume><year>2022</year><fpage>2084</fpage><pub-id pub-id-type="doi">10.1186/s12889-022-14506-w</pub-id><pub-id pub-id-type="pmid">36380298</pub-id><pub-id pub-id-type="pmcid">PMC9664696</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><volume>5</volume><year>2022</year><fpage>e2243597</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.43597</pub-id><pub-id pub-id-type="pmid">36416824</pub-id><pub-id pub-id-type="pmcid">PMC9685490</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Buxton</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Scheuermeyer</surname><given-names>F.X.</given-names></name><etal/></person-group><article-title>Risk of cardiovascular diseases in relation to substance use disorders</article-title><source>Drug Alcohol Depend</source><volume>229</volume><year>2021</year><object-id pub-id-type="publisher-id">109132</object-id><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109132</pub-id><pub-id pub-id-type="pmid">34768052</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="book" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Maguire</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Minervini</surname><given-names>V.</given-names></name></person-group><part-title>Interactions between opioids and stimulants: behavioral pharmacology of abuse-related effects</part-title><source>Advances in Pharmacology</source><year>2022</year><publisher-name>Elsevier</publisher-name><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/bs.apha.2021.10.002</pub-id><pub-id pub-id-type="pmid">35341563</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Cicero</surname><given-names>T.J.</given-names></name></person-group><article-title>Polysubstance use trends and variability among individuals with opioid use disorder in rural versus urban settings</article-title><source>Prev Med</source><volume>152</volume><year>2021</year><object-id pub-id-type="publisher-id">106729</object-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106729</pub-id><pub-id pub-id-type="pmid">34293380</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Gisev</surname><given-names>N.</given-names></name><name name-style="western"><surname>Buizen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>R.E.</given-names></name><etal/></person-group><article-title>Five-year trajectories of prescription opioid use</article-title><source>JAMA Netw Open</source><volume>6</volume><year>2023</year><fpage>e2328159</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.28159</pub-id><pub-id pub-id-type="pmid">37561463</pub-id><pub-id pub-id-type="pmcid">PMC10415961</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Binswanger</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Shetterly</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Opioid dose trajectories and associations with mortality, opioid use disorder, continued opioid therapy, and health plan disenrollment</article-title><source>JAMA Netw Open</source><volume>5</volume><year>2022</year><fpage>e2234671</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.34671</pub-id><pub-id pub-id-type="pmid">36197665</pub-id><pub-id pub-id-type="pmcid">PMC9535531</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Abebe</surname><given-names>K.Z.</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Trajectories of opioid use following first opioid prescription in opioid-naive youths and young adults</article-title><source>JAMA Netw Open</source><volume>4</volume><year>2021</year><fpage>e214552</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.4552</pub-id><pub-id pub-id-type="pmid">33885777</pub-id><pub-id pub-id-type="pmcid">PMC8063062</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Shulman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wai</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>E.V.</given-names></name></person-group><article-title>Buprenorphine treatment for opioid use disorder: an overview</article-title><source>CNS Drugs</source><volume>33</volume><year>2019</year><fpage>567</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1007/s40263-019-00637-z</pub-id><pub-id pub-id-type="pmid">31062259</pub-id><pub-id pub-id-type="pmcid">PMC6585403</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Nguena Nguefack</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Pag&#233;</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches</article-title><source>Clin Epidemiol</source><volume>12</volume><year>2020</year><fpage>1205</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.2147/CLEP.S265287</pub-id><pub-id pub-id-type="pmid">33154677</pub-id><pub-id pub-id-type="pmcid">PMC7608582</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Straub</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-D&#237;az</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>B.T.</given-names></name><etal/></person-group><article-title>Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study</article-title><source>JAMA Intern Med</source><volume>182</volume><year>2022</year><fpage>522</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2022.0375</pub-id><pub-id pub-id-type="pmid">35343998</pub-id><pub-id pub-id-type="pmcid">PMC8961398</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kugeler</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Marx</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Hinckley</surname><given-names>A.F.</given-names></name></person-group><article-title>Use of commercial claims data for evaluating trends in Lyme disease diagnoses, United States, 2010&#8211;2018</article-title><source>Emerg Infect Dis</source><volume>27</volume><year>2021</year><fpage>499</fpage><pub-id pub-id-type="doi">10.3201/eid2702.202728</pub-id><pub-id pub-id-type="pmid">33496238</pub-id><pub-id pub-id-type="pmcid">PMC7853566</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Abel</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Bramness</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Martinsen</surname><given-names>E.W.</given-names></name></person-group><article-title>Stimulant medication for ADHD in opioid maintenance treatment</article-title><source>J&#160;Dual Diagn</source><volume>10</volume><year>2014</year><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1080/15504263.2013.867657</pub-id><pub-id pub-id-type="pmid">25392060</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Purdy</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Blondell</surname><given-names>R.D.</given-names></name></person-group><article-title>The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits</article-title><source>J&#160;Addict Dis</source><volume>27</volume><year>2008</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1300/J069v27n01_01</pub-id><pub-id pub-id-type="pmid">18551883</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Buonora</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Starrels</surname><given-names>J.L.</given-names></name></person-group><article-title>Race and gender are associated with opioid dose reduction among patients on chronic opioid therapy</article-title><source>Pain Med</source><volume>20</volume><year>2019</year><fpage>1519</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.1093/pm/pny137</pub-id><pub-id pub-id-type="pmid">30032197</pub-id><pub-id pub-id-type="pmcid">PMC6686117</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chernew</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Sherry</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Maestas</surname><given-names>N.</given-names></name></person-group><article-title>Initial opioid prescriptions among U.S. commercially insured patients, 2012&#8211;2017</article-title><source>N&#160;Engl J Med</source><volume>380</volume><year>2019</year><fpage>1043</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1056/NEJMsa1807069</pub-id><pub-id pub-id-type="pmid">30865798</pub-id><pub-id pub-id-type="pmcid">PMC6487883</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Daumit</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>D.E.</given-names></name></person-group><article-title>Opioid prescriptions by US primary care physicians from 1992 to 2001</article-title><source>J&#160;Pain</source><volume>7</volume><year>2006</year><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2005.11.006</pub-id><pub-id pub-id-type="pmid">16618466</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Flores</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>B.L.</given-names></name></person-group><article-title>Examining racial/ethnic differences in patterns of opioid prescribing: results from an urban safety-net healthcare system</article-title><source>J&#160;Racial Ethn Health Disparities</source><volume>11</volume><year>2024</year><fpage>719</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1007/s40615-023-01555-z</pub-id><pub-id pub-id-type="pmid">36892815</pub-id><pub-id pub-id-type="pmcid">PMC9997438</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Senior</surname><given-names>K.</given-names></name></person-group><article-title>Racial disparities in pain management in the USA</article-title><source>Lancet Oncol</source><volume>9</volume><year>2008</year><fpage>96</fpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70014-7</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0235">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary Figures&#160;and Tables</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0230">We acknowledge the funding for the project provided by the <funding-source id="gs4">National Institute of General Medical Sciences</funding-source> (R01GM141279), and the <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source> (K01DA059572), and the <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source> (2145625).</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0240">Supplementary data related to this article can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.lana.2025.101030" id="intref0015">https://doi.org/10.1016/j.lana.2025.101030</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>